• Eli Lilly recently reported past fourth-quarter 2025 and full-year results showing higher sales and net income, issued 2026 revenue guidance of US$80.00 billion to US$83.00 billion, completed US$4.08 billion of share repurchases under its 2024 buyback, and agreed to acquire Orna Therapeutics for up to US$2.40 billion in cash.
• Together with preparing substantial pre-launch inventory for its experimental oral GLP-1 pill orforglipron, these moves highlight how Eli Lilly is reinforcing its obesity and diabetes franchise while extending into genetic medicines and AI-enabled drug discovery.
• We’ll now examine how Lilly’s strong GLP-1-driven earnings and upcoming orforglipron launch may influence its existing investment narrative.

Find 53 companies with promising cash flow potential yet trading below their fair value.

Eli Lilly Investment Narrative Recap

To own Eli Lilly today, you need to believe its GLP-1 franchise can stay at the center of obesity and diabetes care while new platforms like genetic medicines and AI-powered R&D gradually broaden the story. The key short term catalyst is the potential U.S. approval and launch of orforglipron, with recent inventory build and 2026 revenue guidance reinforcing that focus. The biggest current risk remains pricing and access pressure on its incretin drugs, which this week’s news does not materially reduce.

The most relevant update here is Lilly’s 2026 revenue guidance of US$80.0 billion to US$83.0 billion, issued alongside its strong 2025 results. That outlook effectively embeds management’s expectations around ongoing GLP-1 demand and a potential orforglipron launch, giving investors a clearer yardstick against earlier analyst scenarios. How well Lilly executes on this guidance, particularly in the face of payer decisions and evolving reimbursement, will be central to how the orforglipron catalyst ultimately plays out.

But behind Lilly’s headline guidance, investors should be aware that concentrated dependence on incretin drugs could quickly become a problem if...

Eli Lilly's narrative projects $89.1 billion revenue and $34.2 billion earnings by 2028. This requires 18.7% yearly revenue growth and a $20.4 billion earnings increase from $13.8 billion today.

Uncover how Eli Lilly's forecasts yield a $1093 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were modeling Lilly’s revenue reaching about US$102 billion and earnings of US$40 billion by 2028, so you should recognize how much more upbeat they are compared with consensus and consider how the latest GLP 1 momentum and formulary risk might shift those expectations.

Explore 29 other fair value estimates on Eli Lilly - why the stock might be worth 15% less than the current price!

Build Your Own Eli Lilly Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.